CIPRO 500 MG BT 14

Treatment of the following infections. Particular attention should be paid to information available on bacterial resistance to ciprofloxacin before initiating treatment. Official recommendations regarding the appropriate use of antibacterial should be taken into account.

In adults :

• Lower respiratory tract infections due to gram-negative bacteria.
• Exacerbations of chronic obstructive pulmonary disease.
• Bronchopulmonary infections in cases of cystic fibrosis or bronchiectasis.
• Chronic purulent otitis media.
• Acute exacerbations of chronic sinusitis, particularly due to gram-negative bacteria.
• Urinary tract infections.
• Genital tract infections.
• Gonococcal urethritis and cervicitis due to susceptible strains of Neisseria gonorrhoeae.
• Orchitis-epididymitis, including infections due to susceptible strains of Neisseria gonorrhoeae or upper gynecological. infections, including infections due to susceptible strains of Neisseria gonorrhoeae.
• Gastrointestinal infections (e.g. traveler's diarrhea).
• Intra-abdominal infection.
• Skin and soft tissue infections due to gram-negative bacteria.
• Malignant external otitis.
• Osteoarticular infections.
• Prophylaxis of invasive Neisseria meningitidis infections.
• Anthrax (prophylaxis after exposure and curative treatment).

Ciprofloxacin may be used to treat febrile neutropenic patients suspected of having a bacterial origin.

In children and adolescents :

• Bronchopulmonary infections in cases of cystic fibrosis due to Pseudomonas aeruginosa.
• Complicated urinary tract infections and pyelonephritis.
• Anthrax (prophylaxis after exposure and curative treatment).

Ciprofloxacin may also be used to treat severe infections in children and adolescents, if necessary. Treatment should be exclusively initiated by experienced physicians in the treatment of cystic fibrosis and/or severe infections in children and adolescents.